Cytori Therapeutics Inc (NASDAQ:CYTX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Monday.
According to Zacks, “Cytori Therapeutics, Inc. is discovering and developing proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue, also known as fat. The Company’s preclinical investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders, and new approaches for aesthetic and reconstructive surgery. To facilitate processing and delivery of adipose stem and regenerative cells, Cytori has developed its proprietary Celution System to isolate and concentrate a patient’s own stem and regenerative cells in about an hour. This system will dramatically improve the speed in which personalized cell-based therapies can be delivered to patients. “
Several other equities analysts have also recently issued reports on CYTX. Maxim Group reissued a “buy” rating and issued a $5.00 price objective on shares of Cytori Therapeutics in a report on Tuesday, December 6th. B. Riley initiated coverage on Cytori Therapeutics in a report on Friday, December 16th. They issued a “buy” rating and a $5.75 price objective for the company.
Cytori Therapeutics (NASDAQ:CYTX) remained flat at $1.65 during midday trading on Monday. 34,863 shares of the company traded hands. Cytori Therapeutics has a 1-year low of $1.36 and a 1-year high of $5.44. The firm’s 50-day moving average price is $1.68 and its 200-day moving average price is $1.74. The firm’s market capitalization is $33.83 million.
Your IP Address:
A hedge fund recently raised its stake in Cytori Therapeutics stock. Creative Planning raised its stake in shares of Cytori Therapeutics Inc (NASDAQ:CYTX) by 9,659.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 78,077 shares of the company’s stock after buying an additional 77,277 shares during the period. Creative Planning owned about 0.38% of Cytori Therapeutics worth $158,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 14.17% of the company’s stock.
About Cytori Therapeutics
Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.
Receive News & Ratings for Cytori Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.